Abcellera Biologics Inc
ABCL
查看详细走势图
3.160USD
+0.380+13.67%
收盘 02/06, 16:00（美东）报价延迟15分钟
944.88M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+13.67%
5天
-12.71%
1月
-23.49%
6月
-25.47%
今年开始到现在
-7.60%
1年
+1.94%
查看详细走势图
TradingKey Abcellera Biologics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Abcellera Biologics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名108/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.83。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Abcellera Biologics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Abcellera Biologics Inc亮点
亮点风险
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
业绩增长期
公司处于发展阶段，最新年度总收入28.83M美元
估值合理
公司最新PE估值-5.48，处于3年历史合理位
机构减仓
最新机构持股112.27M股，环比减少0.09%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值42.69K
活跃度降低
近期活跃度降低，过去20天平均换手率0.75
分析师目标
根据
8
位分析师
买入
评级
9.833
目标均价
+200.71%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Abcellera Biologics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Abcellera Biologics Inc简介
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
公司代码ABCL
公司Abcellera Biologics Inc
CEOHansen (Carl L.G)
网址https://www.abcellera.com/
相关品种
